Evaluation of Excede® Given at Either Initial Processing or Revaccination on Bovine Respiratory Disease and Pasture vs. Feedlot Receiving Systems

Authors

Virgil R. Bremer, University of Nebraska-LincolnFollow
Galen E. Erickson, University of Nebraska-LincolnFollow
Terry J. Klopfenstein, University of Nebraska-LincolnFollow
Kyle J. Vander Pol, University of Nebraska-Lincoln
Matthew A. Greenquist, University of Nebraska-LincolnFollow
David R. Smith, University of Nebraska-LincolnFollow
Dee Griffin, University of Nebraska-LincolnFollow
Gary E. Sides, Pfizer Animal Health, New York, N.Y.
Lonty Bryant, Pfizer Animal Health, New York, N.Y.

Date of this Version

January 2007

Comments

Published in 2007 Nebraska Beef Cattle Report. Copyright © 2006 The Board of Regents of the University of Nebraska.

Abstract

An experiment (Exp. 1) was conducted to determine the effect of Excede® at arrival or at revaccination on morbidity, mortality, and gain in both feedlot and pasture receiving systems. A second experiment (Exp. 2) was conducted to determine the effect of feedlot and pasture receiving systems on animal health. In Exp. 1, no treatment differences were observed for initial or final BW, or ADG. In Exp. 1, initial BW, treatment, receiving system (pasture or feedlot); and buyer of cattle explained the cumulative incidence of bovine respiratory disease (BRD). The incidence of BRD in this study was 4.7%, 11.0%, and 13.8% for arrival, control, and revaccination treatments respectively. The arrival medication effectively reduced BRD incidence. BRD was less (P= 0.02) for pasture receiving than feedlot receiving, averaging 7.4% and 11.0% respectively. In Exp. 2 BRD was less for pasture receiving than feedlot receiving with 23% and 53% treated for BRD respectively.